Adrenal cortex and its disorders

Pediatric Endocrinology: Fourth Edition

Volumn , Issue , 2014, Pages

  Miller, Walter L ^a   Flück, Christa E ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84901255684     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4557-4858-7.00022-6     Document Type: Chapter

References (279)

1. Miller W.L. A brief history of adrenal research. Steroidogenesis-the soul of the adrenal. Mol Cell Endocrinol 2013, 371:5-14.
2. Miller W.L. Molecular biology of steroid hormone synthesis. Endocr Rev 1988, 9:295-318.
3. Evans R.M. The steroid and thyroid hormone receptor superfamily. Science 1988, 240:889-895.
4. Else T., Hammer G.D. Genetic analysis of adrenal absence. agenesis and aplasia. Trends Endocrinol Metab 2005, 16:458-468.
5. Mesiano S., Jaffe R.B. Developmental and functional biology of the primate fetal adrenal cortex. Endocr Rev 1997, 18:378-403.
6. Hammer G.D., Parker K.L., Schimmer B.P. Transcriptional regulation of adrenocortical development. Endocrinology 2005, 146:1018-1024.
7. Kim A.C., Barlaskar F.M., Heaton J.H., et al. In search of adrenocortical stem and progenitor cells. Endocr Rev 2009, 30:241-263.
8. Axelrod J., Reisine T.D. Stress hormones. their interaction and regulation. Science 1984, 224:452-459.
9. Miller W.L., Auchus R.J. The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocr Rev 2011, 32:81-151.
10. Miller W.L., Bose H.S. Early steps in steroidogenesis. intracellular cholesterol trafficking. J Lipid Res 2011, 52:2111-2135.
11. Agarwal A.K., Auchus R.J. Cellular redox state regulates hydroxysteroid dehydrogenase activity and intracellular hormone potency. Endocrinology 2005, 146:2531-2538.
12. Miller W.L. Regulation of steroidogenesis by electron transfer. Endocrinology 2005, 146:2544-2550.
13. Stocco D.M., Clark B.J. Regulation of the acute production of steroids in steroidogenic cells. Endocr Rev 1996, 17:221-244.
14. Miller W.L. StAR search-what we know about how the steroidogenic acute regulatory protein mediates mitochondrial cholesterol import. Mol Endocrinol 2007, 21:589-601.
15. Lin D., Sugawara T., Strauss J.F., et al. Role of steroidogenic acute regulatory protein in adrenal and gonadal steroidogenesis. Science 1995, 267:1828-1831.
16. Bose H.S., Sugawara T., Strauss J.F., Miller W.L. The pathophysiology and genetics of congenital lipoid adrenal hyperplasia. N Engl J Med 1996, 335:1870-1878.
17. Bose H.S., Lingappa V.R., Miller W.L. Rapid regulation of steroidogenesis by mitochondrial protein import. Nature 2002, 417:87-91.
18. Papadopoulos V., Miller W.L. Role of mitochondria in steroidogenesis. Best Pract Res Clin Endocrinol Metab 2012, 26:771-790.
19. 54 isomerase gene family. Endocr Rev 2005, 26:525-582.
20. Auchus R.J., Lee T.C., Miller W.L. Cytochrome b5 augments the 17,20-lyase activity of human P450c17 without direct electron transfer. J Biol Chem 1998, 273:3158-3165.
21. Miller W.L. The syndrome of 17,20 lyase deficiency. J Clin Endocrinol Metab 2012, 97:59-67.
22. Speiser P.W., Azziz R., Baskin L.S., et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency. an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010, 95:4133-4160.
23. Morel Y., Miller W.L. Clinical and molecular genetics of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Adv Hum Genet 1991, 20:1-68.
24. Speiser P.W., White P.C. Congenital adrenal hyperplasia. N Engl J Med 2003, 349:776-788.
25. Mellon S.H., Miller W.L. Extraadrenal steroid 21-hydroxylation is not mediated by P450c21. J Clin Invest 1989, 84:1497-1502.
26. Yamazaki H., Shimada T. Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys 1997, 346:161-169.
27. Gomes L.G., Huang N., Agrawal V., et al. Extraadrenal 21-hydroxylation by CYP2C19 and CYP3A4. effect on 21-hydroxylase deficiency. J Clin Endocrinol Metab 2009, 94:89-95.
28. White P.C., Curnow K.M., Pascoe L. Disorders of steroid 11β-hydroxylase isozymes. Endocr Rev 1994, 15:421-438.
29. Fardella C.E., Miller W.L. Molecular biology of mineralocorticoid metabolism. Annu Rev Nutr 1996, 16:443-470.
30. Labrie F., Luu-The V., Lin S.X., et al. The key role of 17β-hydroxysteroid dehydrogenases in sex steroid biology. Steroids 1997, 62:148-158.
31. Penning T.M. Molecular endocrinology of hydroxysteroid dehydrogenases. Endocr Rev 1997, 18:281-305.
32. Moghrabi N., Andersson S. 17β-hydroxysteroid dehydrogenases. physiological roles in health and disease. Trends Endocrinol Metab 1998, 9:265-270.
33. Penning T.M., Burczynski M.E., Jez J.M., et al. Human 3α-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily. functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones. Biochem J 2000, 351:67-77.
34. Nakamura Y., Hornsby P.J., Casson P., et al. Type 5 17β-hydroxysteroid dehydrogenase (AKR1C3) contributes to testosterone production in the adrenal reticularis. J Clin Endocrinol Metab 2009, 94:2192-2198.
35. Falany C.N. Enzymology of human cytosolic sulfotransferases. FASEB J 1997, 11:206-216.
36. Strott C.A. Sulfonation and molecular action. Endocr Rev 2002, 23:703-732.
37. Noordam C., Dhir V., McNelis J.C., et al. Inactivating PAPSS2 mutations in a patient with premature pubarche. N Engl J Med 2009, 360:2310-2318.
38. Simpson E.R., Mahendroo M.S., Means G.D., et al. Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocr Rev 1994, 15:342-355.
39. Grumbach M.M., Auchus R.J. Estrogen. consequences and implications of human mutations in synthesis and action. J Clin Endocrinol Metab 1999, 84:4677-4694.
40. Thigpen A.E., Silver R.I., Guileyardo J.M., et al. Tissue distribution and ontogeny of steroid 5a-reductase isozyme expression. J Clin Invest 1993, 92:903-910.
41. Wilson J.D. The role of androgens in male gender role behavior. Endocr Rev 1999, 20:726-737.
42. White P.C., Mune T., Agarwal A.K. 11β-hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess. Endocr Rev 1997, 18:135-156.
43. Walker E.A., Stewart P.M. 11β-hydroxysteroid dehydrogenase. unexpected connections. Trends Endocrinol Metab 2003, 14:334-339.
44. Seckl J.R., Morton N.M., Chapman K.E., Walker B.R. Glucocorticoids and 11β-hydroxysteroid dehydrogenase in adipose tissue. Recent Prog Horm Res 2004, 59:359-393.
45. Tomlinson J.W., Walker E.A., Bujalska I.J., et al. 11β-hydroxysteroid dehydrogenase type 1. a tissue-specific regulator of glucocorticoid response. Endocr Rev 2004, 25:831-866.
46. Hewitt K.N., Walker E.A., Stewart P.M. Hexose-6-phosphate dehydrogenase and redox control of 11β-hydroxysteroid dehydrogenase type 1 activity. Endocrinology 2005, 146:2539-2543.
47. Auchus R.J. The backdoor pathway to dihydrotestosterone. Trends Endocrinol Metab 2004, 15:432-438.
48. Wilson J.D., Auchus R.J., Leihy M.W., et al. 5α-androstane-3α,17β-diol is formed in tammar wallaby pouch young testes by a pathway involving 5α-pregnane-3α,17α-diol-20-one as a key intermediate. Endocrinology 2003, 144:575-580.
49. Fluck C.E., Meyer-Boni M., Pandey A.V., et al. Why boys will be boys. two pathways of fetal testicular androgen biosynthesis are needed for male sexual differentiation. Am J Hum Genet 2011, 89:201-218.
50. Kamrath C., Hochberg Z., Hartmann M.F., et al. Increased activation of the alternative "backdoor" pathway in patients with 21-hydroxylase deficiency. evidence from urinary steroid hormone analysis. J Clin Endocrinol Metab 2012, 97:E367-E375.
51. Goto M., Piper Hanley K., Marcos J., et al. In humans, early cortisol biosynthesis provides a mechanism to safeguard female sexual development. J Clin Invest 2006, 116:953-960.
52. Miller W.L. Steroid hormone biosynthesis and actions in the materno-feto-placental unit. Clin Perinatol 1998, 25:799-817.
53. McMahon S.K., Pretorius C.J., Ungerer J.P.J., et al. Neonatal complete generalized glucocorticoid resistance and growth hormone deficiency caused by a novel homozygous mutation in helix 12 of the ligand binding domain of the glucocorticoid receptor gene (NR3C1). J Clin Endocrinol Metab 2010, 95:297-302.
54. Sawchenko P.E., Swanson L.W., Vale W.W. Co-expression of corticotropin-releasing factor and vasopressin immunoreactivity in parvocellular neurosecretory neurons of the adrenalectomized rat. Proc Natl Acad Sci U S A 1984, 81:1883-1887.
55. Lundblad J.R., Roberts J.L. Regulation of proopiomelanocortin gene expression in pituitary. Endocr Rev 1988, 9:135-158.
56. Ehrhart-Bornstein M., Hinson J.P., Bornstein S.R., et al. Intraadrenal interactions in the regulation of adrenocortical steroidogenesis. Endocr Rev 1998, 19:101-143.
57. Mesiano S., Jaffe R.B. Role of growth factors in the developmental regulation of the human fetal adrenal cortex. Steroids 1997, 62:62-72.
58. Udelsman R., Norton J.A., Jelenich S.E., et al. Responses of the hypothalamic-pituitary-adrenal and renin-angiotensin axes and the sympathetic system during controlled surgical and anesthetic stress. J Clin Endocrinol Metab 1987, 64:986-994.
59. Taylor L.K., Auchus R.J., Baskin L.S., Miller W.L. Cortisol response to operative stress with anesthesia in healthy children. J Clin Endocrinol Metab 2013, 98:3687-3693.
60. Chrousos G.P. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 1995, 332:1351-1362.
61. Hardman J.A., Hort Y.J., Catanzaro D.F., et al. Primary structure of the human renin gene. DNA 1984, 3:457-468.
62. Barrett P.Q., Bollag W.B., Isales C.M., et al. Role of calcium in angiotensin II-mediated aldosterone secretion. Endocr Rev 1989, 10:496-518.
63. Orentreich N., Brind J.L., Rizer R.L., Vogelman J.H. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J Clin Endocrinol Metab 1984, 59:551-555.
64. Miller W.L. Androgen synthesis in adrenarche. Rev Endocr Metab Disord 2009, 10:3-17.
65. Hui X.G., Akahira J., Suzuki T., et al. Development of the human adrenal zona reticularis. morphometric and immunohistochemical studies from birth to adolescence. J Endocrinol 2009, 203:241-252.
66. Tee M.K., Miller W.L. Phosphorylation of human cytochrome P450c17 by p38α selectively increases 17,20 lyase activity and androgen synthesis. J Biol Chem 2013, 288:22903-23913.
67. Alkatib A.A., Cosma M., Elamin M.B., et al. A systematic review and meta-analysis of randomized placebo-controlled trials of DHEA treatment effects on quality of life in women with adrenal insufficiency. J Clin Endocrinol Metab 2009, 94:3676-3681.
68. Hammond G.L. Molecular properties of corticosteroid binding globulin and the sex-steroid binding proteins. Endocr Rev 1990, 11:65-79.
69. Rosner W. The functions of corticosteroid-binding globulin and sex hormone-binding globulin. recent advances. Endocr Rev 1990, 11:80-91.
70. Dimitriou T., Maser-Gluth C., Remer T. Adrenocortical activity in healthy children is associated with fat mass. Am J Clin Nutr 2003, 77:731-736.
71. Remer T., Maser-Gluth C., Boye K.R., et al. Exaggerated adrenarche and altered cortisol metabolism in Type 1 diabetic children. Steroids 2006, 71:591-598.
72. Kerrigan J.R., Veldhuis J.D., Leyo S.A., et al. Estimation of daily cortisol production and clearance rates in normal pubertal males by deconvolution analysis. J Clin Endocrinol Metab 1993, 76:1505-1510.
73. Linder B.L., Esteban N.V., Yergey A.L., et al. Cortisol production rate in childhood and adolescence. J Pediatr 1990, 117:892-896.
74. Lashansky G., Saenger P., Fishman K., et al. Normative data for adrenal steroidogenesis in a healthy pediatric population. age- and sex-related changes after adrenocorticotropin stimulation. J Clin Endocrinol Metab 1991, 73:674-686.
75. Clark A.J., Weber A. Adrenocorticotropin insensitivity syndromes. Endocr Rev 1998, 19:828-843.
76. Avgerinos P.C., Yanovski J.A., Oldfield E.H., et al. The metyrapone and dexamethasone suppression tests for the differential diagnosis of the adrenocorticotropin-dependent Cushing syndrome. a comparison. Ann Intern Med 1994, 121:318-327.
77. Miller W.L. Congenital lipoid adrenal hyperplasia. the human gene knockout for the steroidogenic acute regulatory protein. J Mol Endocrinol 1997, 19:227-240.
78. Chen X., Baker B.Y., Abduljabbar M.A., Miller W.L. A genetic isolate of congenital lipoid adrenal hyperplasia with atypical clinical findings. J Clin Endocrinol Metab 2005, 90:835-840.
79. Bose H.S., Pescovitz O.H., Miller W.L. Spontaneous feminization in a 46,XX female patient with congenital lipoid adrenal hyperplasia due to a homozygous frameshift mutation in the steroidogenic acute regulatory protein. J Clin Endocrinol Metab 1997, 82:1511-1515.
80. Fujieda K., Tajima T., Nakae J., et al. Spontaneous puberty in 46,XX subjects with congenital lipoid adrenal hyperplasia. ovarian steroidogenesis is spared to some extent despite inactivating mutations in the steroidogenic acute regulatory protein (StAR) gene. J Clin Invest 1997, 99:1265-1271.
81. Baker B.Y., Lin L., Kim C.J., et al. Nonclassic congenital lipoid adrenal hyperplasia. a new disorder of the steroidogenic acute regulatory protein with very late presentation and normal male genitalia. J Clin Endocrinol Metab 2006, 91:4781-4785.
82. Metherell L.A., Naville D., Halaby G., et al. Nonclassic lipoid congenital adrenal hyperplasia masquerading as familial glucocorticoid deficiency. J Clin Endocrinol Metab 2009, 94:3865-3871.
83. Sahakitrungruang T., Soccio R.E., Lang-Muritano M., et al. Clinical, genetic, and functional characterization of four patients carrying partial loss-of-function mutations in the steroidogenic acute regulatory protein (StAR). J Clin Endocrinol Metab 2010, 95:3352-3359.
84. Tajima T., Fujieda K., Kouda N., et al. Heterozygous mutation in the cholesterol side chain cleavage enzyme (P450scc) gene in a patient with 46,XY sex reversal and adrenal insufficiency. J Clin Endocrinol Metab 2001, 86:3820-3825.
85. Tee M.K., Abramsohn M., Loewenthal N., et al. Varied clinical presentations with mutations in CYP11A1 encoding the cholesterol side chain cleavage enzyme, P450scc. J Clin Endocrinol Metab 2013, 98:713-720.
86. Rubtsov P., Karmanov M., Sverdlova P., et al. A novel homozygous mutation in CYP11A1 gene is associated with late-onset adrenal insufficiency and hypospadias in a 46,XY patient. J Clin Endocrinol Metab 2009, 94:936-939.
87. Sahakitrungruang T., Tee M.K., Blackett P.R., Miller W.L. Partial defect in the cholesterol side-chain cleavage enzyme P450scc (CYP11A1) resembling nonclassic congenital lipoid adrenal hyperplasia. J Clin Endocrinol Metab 2011, 96:792-798.
88. Achermann J.C., Ito M., Hindmarsh P.C., Jameson J.L. A mutation in the gene encoding steroidogenic factor-1 causes XY sex reversal and adrenal failure in humans. Nat Genet 1999, 22:125-126.
89. Camats N., Pandey A.V., Fernandez-Cancio M., et al. Ten novel mutations in the NR5A1 gene cause disordered sex development in 46,XY and ovarian insufficiency in 46,XX individuals. J Clin Endocrinol Metab 2012, 97:E1294-E1306.
90. Moisan A.M., Ricketts M.L., Tardy V., et al. New insight into the molecular basis of 3β-hydroxysteroid dehydrogenase deficiency. identification of eight mutations in the HSD3B2 gene eleven patients from seven new families and comparison of the functional properties of twenty-five mutant enzymes. J Clin Endocrinol Metab 1999, 84:4410-4425.
91. Cara J.F., Moshang T., Bongiovanni A.M., Marx B.S. Elevated 17-hydroxyprogesterone and testosterone in a newborn with 3β-hydroxysteroid dehydrogenase deficiency. N Engl J Med 1985, 313:618-621.
92. Pang S., Carbunaru G., Haider A., et al. Carriers for type II 3b-hydroxysteroid dehydrogenase (HSD3B2) deficiency can only be identified by HSD3B2 genotype study and not by hormone test. Clin Endocrinol (Oxf) 2003, 58:323-331.
93. Pang S. The molecular and clinical spectrum of 3β-hydroxysteroid dehydrogenase deficiency disorder. Trends Endocrinol Metab 1998, 9:82-86.
94. Mermejo L.M., Elias L.L., Marui S., et al. Refining hormonal diagnosis of type II 3β-hydroxysteroid dehydrogenase deficiency in patients with premature pubarche and hirsutism based on HSD3B2 genotyping. J Clin Endocrinol Metab 2005, 90:1287-1293.
95. Auchus R.J. The genetics, pathophysiology, and management of human deficiencies of P450c17. Endocrinol Metab Clin North Am 2001, 30:101-119.
96. Costa-Santos M., Kater C.E., Auchus R.J. Two prevalent CYP17 mutations and genotype-phenotype correlations in 24 Brazilian patients with 17-hydroxylase deficiency. J Clin Endocrinol Metab 2004, 89:49-60.
97. Geller D.H., Auchus R.J., Mendonca B.B., Miller W.L. The genetic and functional basis of isolated 17,20-lyase deficiency. Nat Genet 1997, 17:201-205.
98. Auchus R.J., Miller W.L. Molecular modeling of human P450c17 (17α-hydroxylase/17,20-lyase). insights into reaction mechanisms and effects of mutations. Mol Endocrinol 1999, 13:1169-1182.
99. Fluck C.E., Tajima T., Pandey A.V., et al. Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome. Nat Genet 2004, 36:228-230.
100. Huang N., Pandey A.V., Agrawal V., et al. Diversity and function of mutations in P450 oxidoreductase in patients with Antley-Bixler syndrome and disordered steroidogenesis. Am J Hum Genet 2005, 76:729-749.
101. Fukami M., Horikawa R., Nagai T., et al. Cytochrome P450 oxidoreductase gene mutations and Antley-Bixler syndrome with abnormal genitalia and/or impaired steroidogenesis. molecular and clinical studies in 10 patients. J Clin Endocrinol Metab 2005, 90:414-426.
102. Scott R.R., Miller W.L. Genetic and clinical features of P450 oxidoreductase deficiency. Horm Res 2008, 69:266-275.
103. Krone N., Reisch N., Idkowiak J., et al. Genotype-phenotype analysis in congenital adrenal hyperplasia due to P450 oxidoreductase deficiency. J Clin Endocrinol Metab 2012, 97:E257-E267.
104. Shackleton C., Marcos J., Arlt W., & Hauffa B.P. Prenatal diagnosis of P450 oxidoreductase deficiency (ORD). a disorder causing low pregnancy estriol, maternal and fetal virilization, and the Antley-Bixler syndrome phenotype. Am J Med Genet A 2004, 129A:105-112.
105. Laue K., Pogoda H.M., Daniel P.B., et al. Craniosynostosis and multiple skeletal anomalies in humans and zebrafish result from a defect in the localized degradation of retinoic acid. Am J Hum Genet 2011, 89:595-606.
106. Miller W.L., Agrawal V., Sandee D., et al. Consequences of POR mutations and polymorphisms. Mol Cell Endocrinol 2011, 336:174-179.
107. Tomalik-Scharte D., Maiter D., Kirchheiner J., et al. Impaired hepatic drug and steroid metabolism in congenital adrenal hyperplasia due to P450 oxidoreductase deficiency. Eur J Endocrinol 2010, 163:919-924.
108. Giordano S.J., Kaftory A., Steggles A.W. A splicing mutation in the cytochrome b5 gene from a patient with congenital methemoglobinemia and pseudohermaphrodism. Hum Genet 1994, 93:568-570.
109. Kok R.C., Timmerman M.A., Wolffenbuttel K.P., et al. Isolated 17,20-lyase deficiency due to the cytochrome b5 mutation W27X. J Clin Endocrinol Metab 2010, 95:994-999.
110. Idkowiak J., Randell T., Dhir V., et al. A missense mutation in the human cytochrome b5 gene causes 46,XY disorder of sex development due to true isolated 17,20 lyase deficiency. J Clin Endocrinol Metab 2012, 97:E465-E475.
111. Therrell B.L., Berenbaum S.A., Manter-Kapanke V., et al. Results of screening 1.9 million Texas newborns for 21-hydroxylase-deficient congenital adrenal hyperplasia. Pediatrics 1998, 101:583-590.
112. Witchel S.F. Nonclassic congenital adrenal hyperplasia. Curr Opin Endocrinol Diabetes Obes 2012, 19:151-158.
113. Wijesuriya S.D., Zhang G., Dardis A., Miller W.L. Transcriptional regulatory elements of the human gene for cytochrome P450c21 (steroid 21-hydroxylase) lie within intron 35 of the linked C4B gene. J Biol Chem 1999, 274:38097-38106.
114. Gomez-Escobar N., Chou C.F., Lin W.W., et al. The G11 gene located in the major histocompatibility complex encodes a novel nuclear serine/threonine protein kinase. J Biol Chem 1998, 273:30954-30960.
115. Bristow J., Tee M.K., Gitelman S.E., et al. Tenascin-X. a novel extracellular matrix protein encoded by the human XB gene overlapping P450c21B. J Cell Biol 1993, 122:265-278.
116. Burch G.H., Gong Y., Liu W., et al. Tenascin-X deficiency is associated with Ehlers-Danlos syndrome. Nat Genet 1997, 17:104-108.
117. Schalkwijk J., Zweers M.C., Steijlen P.M., et al. A recessive form of the Ehlers-Danlos syndrome caused by tenascin-X deficiency. N Engl J Med 2001, 345:1167-1175.
118. Miller W.L. Dexamethasone treatment of congenital adrenal hyperplasia in utero. an experimental therapy of unproven safety. J Urol 1999, 162:537-540.
119. Miller W.L., Witchel S.F. Prenatal treatment of congenital adrenal hyperplasia. Risks outweigh benefits. Am J Obstet Gynecol 2013, 208:354-359.
120. Partsch C.J., Sippell W.G., MacKenzie I.Z., Aynsley-Green A. The steroid hormonal milieu of the undisturbed human fetus and mother at 16-20 weeks gestation. J Clin Endocrinol Metab 1991, 73:969-974.
121. Kari M.A., Raivio K.O., Stenman U.H., Voutilainen R. Serum cortisol, dehydroepiandrosterone sulfate, and steroid-binding globulins in preterm neonates. effect of gestational age and dexamethasone therapy. Pediatr Res 1996, 40:319-324.
122. Witchel S.F., Miller W.L. Prenatal treatment of congenital adrenal hyperplasia-not standard of care. J Genet Couns 2012, 21:615-624.
123. Hirvikoski T., Nordenstrom A., Lindholm T., et al. Cognitive functions in children at risk for congenital adrenal hyperplasia treated prenatally with dexamethasone. J Clin Endocrinol Metab 2007, 92:542-548.
124. Hirvikoski T., Nordenstrom A., Lindholm T., et al. Long-term follow-up of prenatally treated children at risk for congenital adrenal hyperplasia. does dexamethasone cause behavioural problems. Eur J Endocrinol 2008, 159:309-316.
125. Hirvikoski T., Lindholm T., Lajic S., Nordenstrom A. Gender role behaviour in prenatally dexamethasone-treated children at risk for congenital adrenal hyperplasia. a pilot study. Acta Paediatr 2011, 100:e112-e119.
126. Hirvikoski T., Nordenstrom A., Wedell A., et al. Prenatal dexamethasone treatment of children at risk for congenital adrenal hyperplasia. the Swedish experience and standpoint. J Clin Endocrinol Metab 2012, 97:1881-1883.
127. Chabraoui L., Abid F., Menassa R., et al. Three novel CYP11B1 mutations in congenital adrenal hyperplasia due to steroid 11β-hydroxylase deficiency in a Moroccan population. Horm Res Paediatr 2010, 74:182-189.
128. Parajes S., Loidi L., Reisch N., et al. Functional consequences of seven novel mutations in the CYP11B1 gene. four mutations associated with nonclassic and three mutations causing classic 11β-hydroxylase deficiency. J Clin Endocrinol Metab 2010, 95:779-788.
129. Joehrer K., Geley S., Strasser-Wozak E.M., et al. CYP11B1 mutations causing non-classic adrenal hyperplasia due to 11β-hydroxylase deficiency. Hum Mol Genet 1997, 6:1829-1834.
130. Pascoe L., Curnow K.M., Slutsker L., et al. Mutations in the human CYP11B2 (aldosterone synthase) gene causing corticosterone methyloxidase II deficiency. Proc Natl Acad Sci U S A 1992, 89:4996-5000.
131. Dluhy R.G., Lifton R.P. Glucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab 1999, 84:4341-4344.
132. Fardella C.E., Mosso L., Gomez-Sanchez C., et al. Primary hyperaldosteronism in essential hypertensives. prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 2000, 85:1863-1867.
133. Furst-Recktenwald S., Dorr H.G., Quinkler M., et al. Is there sufficient evidence to consider the use of 11β-hydroxysteroid dehydrogenase type 1 inhibition in children. Clin Endocrinol (Oxf) 2012, 77:159-168.
134. Lawson A.J., Walker E.A., Lavery G.G., et al. Cortisone-reductase deficiency associated with heterozygous mutations in 11β-hydroxysteroid dehydrogenase type 1. Proc Natl Acad Sci U S A 2011, 108:4111-4116.
135. Lavery G.G., Walker E.A., Tiganescu A., et al. Steroid biomarkers and genetic studies reveal inactivating mutations in hexose-6-phosphate dehydrogenase in patients with cortisone reductase deficiency. J Clin Endocrinol Metab 2008, 93:3827-3832.
136. Draper N., Walker E.A., Bujalska I.J., et al. Mutations in the genes encoding 11β-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase interact to cause cortisone reductase deficiency. Nat Genet 2003, 34:434-439.
137. San Millan J.L., Botella-Carretero J.I., Alvarez-Blasco F., et al. A study of the hexose-6-phosphate dehydrogenase gene R453Q and 11β-hydroxysteroid dehydrogenase type 1 gene 83557insA polymorphisms in the polycystic ovary syndrome. J Clin Endocrinol Metab 2005, 90:4157-4162.
138. White P.C. Genotypes at 11β-hydroxysteroid dehydrogenase type 11B1 and hexose-6-phosphate dehydrogenase loci are not risk factors for apparent cortisone reductase deficiency in a large population-based sample. J Clin Endocrinol Metab 2005, 90:5880-5883.
139. Quinkler M., Stewart P.M. Hypertension and the cortisol-cortisone shuttle. J Clin Endocrinol Metab 2003, 88:2384-2392.
140. Palermo M., Quinkler M., Stewart P.M. Apparent mineralocorticoid excess syndrome. an overview. Arq Bras Endocrinol Metabol 2004, 48:687-696.
141. Perry R., Kecha O., Paquette J., et al. Primary adrenal insufficiency in children. twenty years experience at the Sainte-Justine Hospital, Montreal. J Clin Endocrinol Metab 2005, 90:3243-3250.
142. Lin L., Gu W.X., Ozisik G., et al. Analysis of DAX1 (NR0B1) and steroidogenic factor-1 (NR5A1) in children and adults with primary adrenal failure. ten years' experience. J Clin Endocrinol Metab 2006, 91:3048-3054.
143. Lin L., Achermann J.C. Inherited adrenal hypoplasia. not just for kids. Clin Endocrinol (Oxf) 2004, 60:529-537.
144. Adem P.V., Montgomery C.P., Husain A.N., et al. Staphylococcus aureus sepsis and the Waterhouse-Friderichsen syndrome in children. N Engl J Med 2005, 353:1245-1251.
145. Betterle C., Dal Pra C., Mantero F., Zanchetta R. Autoimmune adrenal insufficiency and autoimmune polyendocrine syndromes. autoantibodies, autoantigens, and their applicability in diagnosis and disease prediction. Endocr Rev 2002, 23:327-364.
146. Ueda H., Howson J.M., Esposito L., et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003, 423:506-511.
147. Ghaderi M., Gambelunghe G., Tortoioli C., et al. MHC2TA single nucleotide polymorphism and genetic risk for autoimmune adrenal insufficiency. J Clin Endocrinol Metab 2006, 91:4107-4111.
148. Perheentupa J. Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. J Clin Endocrinol Metab 2006, 91:2843-2850.
149. Finnish-German A.C. An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains. Nat Genet 1997, 17:399-403.
150. Nagamine K., Peterson P., Scott H.S., et al. Positional cloning of the APECED gene. Nat Genet 1997, 17:393-398.
151. Villasenor J., Benoist C., Mathis D. AIRE and APECED. molecular insights into an autoimmune disease. Immunol Rev 2005, 204:156-164.
152. Tabarin A., Achermann J.C., Recan D., et al. A novel mutation in DAX1 causes delayed-onset adrenal insufficiency and incomplete hypogonadotropic hypogonadism. J Clin Invest 2000, 105:321-328.
153. Vilain E., Le Merrer M., Lecointre C., et al. IMAGe, a new clinical association of intrauterine growth retardation, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomalies. J Clin Endocrinol Metab 1999, 84:4335-4340.
154. Bergada I., Del Rey G., Lapunzina P., et al. Familial occurrence of the IMAGe association. additional clinical variants and a proposed mode of inheritance. J Clin Endocrinol Metab 2005, 90:3186-3190.
155. Arboleda A.V., Lee H., Parnaik R., et al. Mutations in the PCNA-binding domain of CDKN1C cause IMAGe syndrome. Nat Genet 2012, 44:788-792.
156. Hatada I., Ohashi H., Fukushima Y., et al. An imprinted gene p57KIP2 is mutated in Beckwith-Wiedemann syndrome. Nat Genet 1996, 14:171-173.
157. Clark A.J.L., Metherell L.A., Cheetham M.E., Huebner A. Inherited ACTH insensitivity illuminates the mechanisms of ACTH action. Trends Endocrinol Metab 2005, 16:451-457.
158. Webb T.R., Clark A.J.L. The melanocortin 2 receptor accessory proteins. Mol Endocrinol 2010, 24:475-484.
159. Metherell L.A., Chapple J.P., Cooray S., et al. Mutations in MRAP, encoding a new interacting partner of the ACTH receptor, cause familial glucocorticoid deficiency type 2. Nat Genet 2005, 37:166-170.
160. Meimaridou E., Kowalczyk J., Guasti L., et al. Mutations in NNT encoding nicotinamide nucleotide transhydrogenase cause familial glucocorticoid deficiency. Nat Genet 2012, 44:740-742.
161. Hughes C.R., Guasti L., Meimaridou E., et al. MCM4 mutation causes adrenal failure, short stature, and natural killer cell deficiency in humans. J Clin Invest 2012, 122:814-820.
162. Tullio-Pelet A., Salomon R., Hadj-Rabia S., et al. Mutant WD-repeat protein in triple-A syndrome. Nat Genet 2000, 26:332-335.
163. Handschug K., Sperling S., Yoon S.J., et al. Triple A syndrome is caused by mutations in AAAS, a new WD-repeat protein gene. Hum Mol Genet 2001, 10:283-290.
164. Storr H.L., Kind B., Parfitt D.A., et al. Deficiency of ferritin heavy-chain nuclear import in triple a syndrome implies nuclear oxidative damage as the primary disease mechanism. Mol Endocrinol 2009, 23:2086-2094.
165. Ligtenberg M.J., Kemp S., Sarde C.O., et al. Spectrum of mutations in the gene encoding the adrenoleukodystrophy protein. Am J Hum Genet 1995, 56:44-50.
166. Watkins P.A., Gould S.J., Smith M.A., et al. Altered expression of ALDP in X-linked adrenoleukodystrophy. Am J Hum Genet 1995, 57:292-301.
167. Shimozawa N. Molecular and clinical findings and diagnostic flowchart of peroxisomal diseases. Brain Dev 2011, 33:770-776.
168. Moser H.W., Raymond G.V., Dubey P. Adrenoleukodystrophy. new approaches to a neurodegenerative disease. JAMA 2005, 294:3131-3134.
169. McGuinness M.C., Lu J.F., Zhang H.P., et al. Role of ALDP (ABCD1) and mitochondria in X-linked adrenoleukodystrophy. Mol Cell Biol 2003, 23:744-753.
170. Kemp S., Wanders R.J. X-linked adrenoleukodystrophy. very long-chain fatty acid metabolism, ABC half-transporters and the complicated route to treatment. Mol Genet Metab 2007, 90:268-276.
171. Watkins P.A., Naidu S., Moser H.W. Adrenoleukodystrophy. biochemical procedures in diagnosis, prevention and treatment. J Inherit Metab Dis 1987, 10(Suppl. 1):46-53.
172. Moser H.W., Moser A.E., Singh I., O'Neill B.P. Adrenoleukodystrophy. survey of 303 casesbiochemistry, diagnosis, and therapy. Ann Neurol 1984, 16:628-641.
173. Moser H.W. Adrenoleukodystrophy. Curr Opin Neurol 1995, 8:221-226.
174. Laureti S., Casucci G., Santeusanio F., et al. X-linked adrenoleukodystrophy is a frequent cause of idiopathic Addison's disease in young adult male patients. J Clin Endocrinol Metab 1996, 81:470-474.
175. Sadeghi-Nejad A., Senior B. Adrenomyeloneuropathy presenting as Addison's disease in childhood. N Engl J Med 1990, 322:13-16.
176. Peters C., Charnas L.R., Tan Y., et al. Cerebral X-linked adrenoleukodystrophy. the international hematopoietic cell transplantation experience from 1982 to 1999. Blood 2004, 104:881-888.
177. Engelen M., Ofman R., Dijkgraaf M.G., et al. Lovastatin in X-linked adrenoleukodystrophy. N Engl J Med 2010, 362:276-277.
178. Steinberg S., Chen L., Wei L., et al. The PEX Gene Screen. molecular diagnosis of peroxisome biogenesis disorders in the Zellweger syndrome spectrum. Mol Genet Metab 2004, 83:252-263.
179. Wanders R.J.A., Waterham H.R. Peroxisomal disorders I. biochemistry and genetics of peroxisome biogenesis disorders. Clin Genet 2005, 67:107-133.
180. Mandel H., Korman S.H. Phenotypic variability (heterogeneity) of peroxisomal disorders. Adv Exp Med Biol 2003, 544:9-30.
181. Klima H., Ullrich K., Aslanidis C., et al. A splice junction mutation causes deletion of a 72-base exon from the mRNA for lysosomal acid lipase in a patient with cholesteryl ester storage disease. J Clin Invest 1993, 92:2713-2718.
182. Anderson R.A., Byrum R.S., Coates P.M., Sando G.N. Mutations at the lysosomal acid cholesteryl ester hydrolase gene locus in Wolman disease. Proc Natl Acad Sci U S A 1994, 91:2718-2722.
183. Pagani F., Pariyarath R., Garcia R., et al. New lysosomal acid lipase gene mutants explain the phenotype of Wolman disease and cholesteryl ester storage disease. J Lipid Res 1998, 39:1382-1388.
184. Lohse P., Maas S., Sewell A.C., et al. Molecular defects underlying Wolman disease appear to be more heterogeneous than those resulting in cholesteryl ester storage disease. J Lipid Res 1999, 40:221-228.
185. Zschenker O., Jung N., Rethmeier J., et al. Characterization of lysosomal acid lipase mutations in the signal peptide and mature polypeptide region causing Wolman disease. J Lipid Res 2001, 42:1033-1040.
186. Pisciotta L., Fresa R., Bellocchio A., et al. Cholesteryl ester storage disease (CESD) due to novel mutations in the LIPA gene. Mol Genet Metab 2009, 97:143-148.
187. Gramatges M.M., Dvorak C.C., Regula D.P., et al. Pathological evidence of Wolman's disease following hematopoietic stem cell transplantation despite correction of lysosomal acid lipase activity. Bone Marrow Transplant 2009, 44:449-450.
188. Tolar J., Petryk A., Khan K., et al. Long-term metabolic, endocrine, and neuropsychological outcome of hematopoietic cell transplantation for Wolman disease. Bone Marrow Transplant 2009, 43:21-27.
189. Correa-Cerro L.S., Porter F.D. 3β-hydroxysterol ?7-reductase and the Smith-Lemli-Opitz syndrome. Mol Genet Metab 2005, 84:112-126.
190. DeBarber A.E., Eroglu Y., Merkens L.S., et al. Smith-Lemli-Opitz syndrome. Expert Rev Mol Med 2012, 13:e24.
191. Andersson H.C., Frentz J., Martinez J.E., et al. Adrenal insufficiency in Smith-Lemli-Opitz syndrome. Am J Med Genet 1999, 82:382-384.
192. Nicolino M., Ferlin T., Forest M., et al. Identification of a large-scale mitochondrial deoxyribonucleic acid deletion in endocrinopathies and deafness. report of two unrelated cases with diabetes mellitus and adrenal insufficiency, respectively. J Clin Endocrinol Metab 1997, 82:3063-3067.
193. DeVile C.J., Grant D.B., Hayward R.D., Stanhope R. Growth and endocrine sequelae of craniopharyngioma. Arch Dis Child 1996, 75:108-114.
194. Karavitaki N., Brufani C., Warner J.T., et al. Craniopharyngiomas in children and adults. systematic analysis of 121 cases with long-term follow-up. Clin Endocrinol (Oxf) 2005, 62:397-409.
195. Rose S.R., Danish R.K., Kearney N.S., et al. ACTH deficiency in childhood cancer survivors. Pediatr Blood Cancer 2005, 45:808-813.
196. Mendonca B.B., Osorio M.G., Latronico A.C., et al. Longitudinal hormonal and pituitary imaging changes in two females with combined pituitary hormone deficiency due to deletion of A301,G302 in the PROP1 gene. J Clin Endocrinol Metab 1999, 84:942-945.
197. Pernasetti F., Toledo S.P., Vasilyev V.V., et al. Impaired adrenocorticotropin-adrenal axis in combined pituitary hormone deficiency caused by a two-base pair deletion (301-302delAG) in the prophet of Pit-1 gene. J Clin Endocrinol Metab 2000, 85:390-397.
198. Lamolet B., Pulichino A.M., Lamonerie T., et al. A pituitary cell-restricted T box factor, Tpit, activates POMC transcription in cooperation with Pitx homeoproteins. Cell 2001, 104:849-859.
199. Metherell L.A., Savage M.O., Dattani M., et al. TPIT mutations are associated with early-onset, but not late-onset isolated ACTH deficiency. Eur J Endocrinol 2004, 151:463-465.
200. Pulichino A.M., Vallette-Kasic S., Couture C., et al. Human and mouse TPIT gene mutations cause early onset pituitary ACTH deficiency. Genes Dev 2003, 17:711-716.
201. Vallette-Kasic S., Brue T., Pulichino A.M., et al. Congenital isolated adrenocorticotropin deficiency. an underestimated cause of neonatal death, explained by TPIT gene mutations. J Clin Endocrinol Metab 2005, 90:1323-1331.
202. Couture C., Saveanu A., Barlier A., et al. Phenotypic homogeneity and genotypic variability in a large series of congenital isolated ACTH-deficiency patients with TPIT gene mutations. J Clin Endocrinol Metab 2012, 97:E486-E495.
203. Farooqi I.S., Jones M.K., Evans M., et al. Triple H syndrome. a novel autoimmune endocrinopathy characterized by dysfunction of the hippocampus, hair follicle, and hypothalamic-pituitary adrenal axis. J Clin Endocrinol Metab 2000, 85:2644-2648.
204. Samuels M.E., Gallo-Payet N., Pinard S., et al. Isolated glucocorticoid deficiency caused by immunoreactive but biologically inactive ACTH. Horm Res Paed 2012, 78(Suppl. 1):4-5. Abst PL.
205. Krude H., Biebermann H., Luck W., et al. Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Genet 1998, 19:155-157.
206. Krude H., Biebermann H., Schnabel D., et al. Obesity due to proopiomelanocortin deficiency. three new cases and treatment trials with thyroid hormone and ACTH4-10. J Clin Endocrinol Metab 2003, 88:4633-4640.
207. Jackson R.S., Creemers J.W., Ohagi S., et al. Obesity and impaired prohormone processing associated with mutations in the human prohormone convertase 1 gene. Nat Genet 1997, 16:303-306.
208. Jackson R.S., Creemers J.W., Farooqi I.S., et al. Small-intestinal dysfunction accompanies the complex endocrinopathy of human proprotein convertase 1 deficiency. J Clin Invest 2003, 112:1550-1560.
209. Kannisto S., Korppi M., Remes K., Voutilainen R. Adrenal suppression, evaluated by a low dose adrenocorticotropin test, and growth in asthmatic children treated with inhaled steroids. J Clin Endocrinol Metab 2000, 85:652-657.
210. Todd G.R., Acerini C.L., Ross-Russell R., et al. Survey of adrenal crisis associated with inhaled corticosteroids in the United Kingdom. Arch Dis Child 2002, 87:457-461.
211. Paton J., Jardine E., McNeill E., et al. Adrenal responses to low dose synthetic ACTH (Synacthen) in children receiving high dose inhaled fluticasone. Arch Dis Child 2006, 91:808-813.
212. Carpenter P.C. Diagnostic evaluation of Cushing's syndrome. Endocrinol Metab Clin North Am 1988, 17:445-472.
213. McArthur R.G., Cloutier M.D., Hayles A.B., Sprague R.G. Cushing's disease in children. findings in 13 cases. Mayo Clin Proc 1972, 47:318-326.
214. Storr H.L., Isidori A.M., Monson J.P., et al. Prepubertal Cushing's disease is more common in males, but there is no increase in severity at diagnosis. J Clin Endocrinol Metab 2004, 89:3818-3820.
215. Miller W.L., Townsend J.J., Grumbach M.M., Kaplan S.L. An infant with Cushing's disease due to an adrenocorticotropin-producing pituitary adenoma. J Clin Endocrinol Metab 1979, 48:1017-1025.
216. Devoe D.J., Miller W.L., Conte F.A., et al. Long-term outcome in children and adolescents after transsphenoidal surgery for Cushing's disease. J Clin Endocrinol Metab 1997, 82:3196-3202.
217. Joshi S.M., Hewitt R.J., Storr H.L., et al. Cushing's disease in children and adolescents. 20 years of experience in a single neurosurgical center. Neurosurgery 2005, 57:281-285.
218. Kanter A.S., Diallo A.O., Jane J.A., et al. Single-center experience with pediatric Cushing's disease. J Neurosurg 2005, 103:413-420.
219. Tyrrell J.B., Brooks R.M., Fitzgerald P.A., et al. Cushing's disease. selective trans-sphenoidal resection of pituitary microadenomas. N Engl J Med 1978, 298:753-758.
220. Hermus A.R., Smals A.G., Swinkels L.M., et al. Bone mineral density and bone turnover before and after surgical cure of Cushing's syndrome. J Clin Endocrinol Metab 1995, 80:2859-2865.
221. Leong G.M., Abad V., Charmandari E., et al. Effects of child- and adolescent-onset endogenous Cushing syndrome on bone mass, body composition, and growth. a 7-year prospective study into young adulthood. J Bone Miner Res 2007, 22:110-118.
222. Boggan J.E., Tyrrell J.B., Wilson C.B. Transsphenoidal microsurgical management of Cushing's disease. report of 100 cases. J Neurosurg 1983, 59:195-200.
223. Styne D.M., Grumbach M.M., Kaplan S.L., et al. Treatment of Cushing's disease in childhood and adolescence by transsphenoidal microadenomectomy. N Engl J Med 1984, 310:889-893.
224. Magiakou M.A., Mastorakos G., Oldfield E.H., et al. Cushing's syndrome in children and adolescents. presentation, diagnosis, and therapy. N Engl J Med 1994, 331:629-636.
225. Leinung M.C., Kane L.A., Scheithauer B.W., et al. Long term follow-up of transsphenoidal surgery for the treatment of Cushing's disease in childhood. J Clin Endocrinol Metab 1995, 80:2475-2479.
226. Storr H.L., Afshar F., Matson M., et al. Factors influencing cure by transsphenoidal selective adenomectomy in paediatric Cushing's disease. Eur J Endocrinol 2005, 152:825-833.
227. Massoud A.F., Powell M., Williams R.A., et al. Transsphenoidal surgery for pituitary tumours. Arch Dis Child 1997, 76:398-404.
228. Magiakou M.A., Mastorakos G., Chrousos G.P. Final stature in patients with endogenous Cushing's syndrome. J Clin Endocrinol Metab 1994, 79:1082-1085.
229. Lebrethon M.C., Grossman A.B., Afshar F., et al. Linear growth and final height after treatment for Cushing's disease in childhood. J Clin Endocrinol Metab 2000, 85:3262-3265.
230. Davies J.H., Storr H.L., Davies K., et al. Final adult height and body mass index after cure of paediatric Cushing's disease. Clin Endocrinol (Oxf) 2005, 62:466-472.
231. Storr H.L., Plowman P.N., Carroll P.V., et al. Clinical and endocrine responses to pituitary radiotherapy in pediatric Cushing's disease. an effective second-line treatment. J Clin Endocrinol Metab 2003, 88:34-37.
232. Nieman L.K. Medical therapy of Cushing's disease. Pituitary 2002, 5:77-82.
233. Schulte H.M., Benker G., Reinwein D., et al. Infusion of low dose etomidate. correction of hypercortisolemia in patients with Cushing's syndrome and dose-response relationship in normal subjects. J Clin Endocrinol Metab 1990, 70:1426-1430.
234. Greening J.E., Brain C.E., Perry L.A., et al. Efficient short-term control of hypercortisolaemia by low-dose etomidate in severe paediatric Cushing's disease. Horm Res 2005, 64:140-143.
235. Neary N.M., Lopez-Chavez A., Abel B.S., et al. Neuroendocrine ACTH-producing tumor of the thymus. experience with 12 patients over 25 years. J Clin Endocrinol Metab 2012, 97:2223-2230.
236. Perry R.R., Nieman L.K., Cutler G.B., et al. Primary adrenal causes of Cushing's syndrome. diagnosis and surgical management. Ann Surg 1989, 210:59-68.
237. Michalkiewicz E., Sandrini R., Figueiredo B., et al. Clinical and outcome characteristics of children with adrenocortical tumors. a report from the International Pediatric Adrenocortical Tumor Registry. J Clin Oncol 2004, 22:838-845.
238. Ribeiro R.C., Sandrini F., Figueiredo B., et al. An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proc Natl Acad Sci USA 2001, 98:9330-9335.
239. Wolthers O.D., Cameron F.J., Scheimberg I., et al. Androgen secreting adrenocortical tumours. Arch Dis Child 1999, 80:46-50.
240. Wieneke J.A., Thompson L.D., Heffess C.S. Adrenal cortical neoplasms in the pediatric population. a clinicopathologic and immunophenotypic analysis of 83 patients. Am J Surg Pathol 2003, 27:867-881.
241. Ribeiro R.C., Pinto E.M., Zambetti G.P., Rodriguez-Galindo C. The International Pediatric Adrenocortical Tumor Registry initiative. contributions to clinical, biological, and treatment advances in pediatric adrenocortical tumors. Mol Cell Endocrinol 2012, 351:37-43.
242. Young W.F., Carney J.A., Musa B.U., et al. Familial Cushing's syndrome due to primary pigmented nodular adrenocortical disease. Reinvestigation 50 years later. N Engl J Med 1989, 321:1659-1664.
243. Stratakis C.A. Cushing syndrome caused by adrenocortical tumors and hyperplasias (corticotropin-independent Cushing syndrome). Endocr Dev 2008, 13:117-132.
244. Rothenbuhler A., Stratakis C.A. Clinical and molecular genetics of Carney complex. Best Pract Res Clin Endocrinol Metab 2010, 24:389-399.
245. Storr H.L., Mitchell H., Swords F.M., et al. Clinical features, diagnosis, treatment and molecular studies in paediatric Cushing's syndrome due to primary nodular adrenocortical hyperplasia. Clin Endocrinol (Oxf) 2004, 61:553-559.
246. Kirschner L.S., Carney J.A., Pack S.D., et al. Mutations of the gene encoding the protein kinase A type 1-(regulatory subunit in patients with the Carney complex. Nat Genet 2000, 26:89-92.
247. Kirschner L.S., Sandrini F., Monbo J., et al. Genetic heterogeneity and spectrum of mutations of the PRKAR1A gene in patients with the Carney complex. Hum Mol Genet 2000, 9:3037-3046.
248. Bossis I., Stratakis C.A. PRKAR1A. normal and abnormal functions. Endocrinology 2004, 145:5452-5458.
249. Bertherat J., Horvath A., Groussin L., et al. Mutations in regulatory subunit type 1A of cyclic adenosine 5'-monophosphate-dependent protein kinase (PRKAR1A). phenotype analysis in 353 patients and 80 different genotypes. J Clin Endocrinol Metab 2009, 94:2085-2091.
250. Almeida M.Q., Stratakis C.A. Carney complex and other conditions associated with micronodular adrenal hyperplasias. Best Pract Res Clin Endocrinol Metab 2010, 24:907-914.
251. Bourdeau I., Matyakhina L., Stergiopoulos S.G., et al. 17q22-24 chromosomal losses and alterations of protein kinase a subunit expression and activity in adrenocorticotropin-independent macronodular adrenal hyperplasia. J Clin Endocrinol Metab 2006, 91:3626-3632.
252. Horvath A., Boikos S., Giatzakis C., et al. A genome-wide scan identifies mutations in the gene encoding phosphodiesterase 11A4 (PDE11A) in individuals with adrenocortical hyperplasia. Nat Genet 2006, 38:794-800.
253. Kirk J.M., Brain C.E., Carson D.J., et al. Cushing's syndrome caused by nodular adrenal hyperplasia in children with McCune-Albright syndrome. J Pediatr 1999, 134:789-792.
254. Newell-Price J., Trainer P., Besser M., Grossman A. The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states. Endocr Rev 1998, 19:647-672.
255. Stratakis C.A., Kirschner L.S., Carney J.A. Clinical and molecular features of the Carney complex. diagnostic criteria and recommendations for patient evaluation. J Clin Endocrinol Metab 2001, 86:4041-4046.
256. Stratakis C.A., Sarlis N., Kirschner L.S., et al. Paradoxical response to dexamethasone in the diagnosis of primary pigmented nodular adrenocortical disease. Ann Intern Med 1999, 131:585-591.
257. Lienhardt A., Grossman A.B., Dacie J.E., et al. Relative contributions of inferior petrosal sinus sampling and pituitary imaging in the investigation of children and adolescents with ACTH-dependent Cushing's syndrome. J Clin Endocrinol Metab 2001, 86:5711-5714.
258. Ilias I., Chang R., Pacak K., et al. Jugular venous sampling. an alternative to petrosal sinus sampling for the diagnostic evaluation of adrenocorticotropic hormone-dependent Cushing's syndrome. J Clin Endocrinol Metab 2004, 89:3795-3800.
259. Choi M., Scholl U.I., Yue P., et al. K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science 2011, 331:768-772.
260. Charmandari E., Sertedaki A., Kino T., et al. A novel point mutation in the KCNJ5 gene causing primary hyperaldosteronism and early-onset autosomal dominant hypertension. J Clin Endocrinol Metab 2012, 97:E1532-E1539.
261. Mulatero P., Tauber P., Zennaro M.C., et al. KCNJ5 mutations in European families with nonglucocorticoid remediable familial hyperaldosteronism. Hypertension 2012, 59:235-240.
262. Scholl U.I., Nelson-Williams C., Yue P., et al. Hypertension with or without adrenal hyperplasia due to different inherited mutations in the potassium channel KCNJ5. Proc Natl Acad Sci U S A 2012, 109:2533-2538.
263. Boulkroun S, Beuschlein F., Rossi G.P., et al. Prevalence, clinical, and molecular correlates of KCNJ5 mutations in primary aldosteronism. Hypertension 2012, 59:592-598.
264. Charmandari E., Kino T., Chrousos G.P. Familial/sporadic glucocorticoid resistance. clinical phenotype and molecular mechanisms. Ann N Y Acad Sci 2004, 1024:168-181.
265. van Rossum E.F.C., van den Akker E.L.T. Glucocorticoid resistance. Endocr Dev 2011, 20:127-136.
266. Hurley D.M., Accili D., Stratakis C.A., et al. Point mutation causing a single amino acid substitution in the hormone binding domain of the glucocorticoid receptor in familial glucocorticoid resistance. J Clin Invest 1991, 87:680-686.
267. Karl M., Lamberts S.W., Detera-Wadleigh S.D., et al. Familial glucocorticoid resistance caused by a splice site deletion in the human glucocorticoid receptor gene. J Clin Endocrinol Metab 1993, 76:683-689.
268. Kino T., Stauber R.H., Resau J.H., et al. Pathologic human GR mutant has a transdominant negative effect on the wild-type GR by inhibiting its translocation into the nucleus. importance of the ligand-binding domain for intracellular GR trafficking. J Clin Endocrinol Metab 2001, 86:5600-5608.
269. Zennaro M.C., Hubert E.L., Fernandes-Rosa F.L. Aldosterone resistance. structural and functional considerations and new perspectives. Mol Cell Endocrinol 2012, 350:206-215.
270. Chang S.S., Grunder S., Hanukoglu A., et al. Mutations in subunits of the epithelial sodium channel cause salt wasting with hyperkalaemic acidosis, pseudohypoaldosteronism type 1. Nat Genet 1996, 12:248-253.
271. Kerem E., Bistritzer T., Hanukoglu A., et al. Pulmonary epithelial sodium-channel dysfunction and excess airway liquid in pseudohypoaldosteronism. N Engl J Med 1999, 341:156-162.
272. Geller D.S., Rodriguez-Soriano J., Vallo-Boado A., et al. Mutations in the mineralocorticoid receptor gene cause autosomal dominant pseudohypoaldosteronism type I. Nat Genet 1998, 19:279-281.
273. Sartorato P., Lapeyraque A.L., Armanini D., et al. Different inactivating mutations of the mineralocorticoid receptor in fourteen families affected by type I pseudohypoaldosteronism. J Clin Endocrinol Metab 2003, 88:2508-2517.
274. Geller D.S., Farhi A., Pinkerton N., et al. Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science 2000, 289:119-123.
275. Chandar J., Abitbol C., Zilleruelo G., et al. Renal tubular abnormalities in infants with hydronephrosis. J Urol 1996, 155:660-663.
276. Oakley R.H., Cidlowski J.A. Cellular processing of the glucocorticoid receptor gene and protein. new mechanisms for generating tissue-specific actions of glucocorticoids. J Biol Chem 2011, 286:3177-3184.
277. Mellon S.H., Griffin L.D. Neurosteroids. biochemistry and clinical significance. Trends Endocrinol Metab 2002, 13:35-43.
278. Grossmann C., Scholz T., Rochel M., et al. Transactivation via the human glucocorticoid and mineralocorticoid receptor by therapeutically used steroids in CV-1 cells. a comparison of their glucocorticoid and mineralocorticoid properties. Eur J Endocrinol 2004, 151:397-406.
279. Streck W.F., Lockwood D.H. Pituitary adrenal recovery following short-term suppression with corticosteroids. Am J Med 1979, 66:910-914.